WVE
WVE clinical trials: Wave Life Sciences, Inc.
Every trial on ClinicalTrials.gov where Wave Life Sciences, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 15
- Trials linked
- 14
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
WVE on the catalyst calendar · WVE registry changes
- Primary completion Sep 2027Sponsor estimatePhase 1/Phase 2NCT06405633A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATDWave Life Sciences USA, Inc. · Alpha-1 Antitrypsin DeficiencyRecruitingWVELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 1/Phase 2NCT06842186A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or ObesityWave Life Sciences USA, Inc. · Overweight and ObesityRecruitingWVELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2026Sponsor estimatePhase 1/Phase 2NCT04906460Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)Wave Life Sciences USA, Inc. · Duchenne Muscular DystrophyActive, not recruitingWVELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 27, 2023ActualPhase 1/Phase 2NCT05683860Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or...Wave Life Sciences USA, Inc. · Amyotrophic Lateral SclerosisTerminatedWVELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2029Sponsor estimatePhase 2NCT07209332Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular DystrophyWave Life Sciences USA, Inc. · Duchenne Muscular DystrophyEnrolling by invitationWVELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 13, 2025ActualPhase 1NCT06186492A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT...Wave Life Sciences USA, Inc. · Alpha-1 Antitrypsin Deficiency (AATD)CompletedWVELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 24, 2024ActualPhase 1/Phase 2NCT05032196Study of WVE-003 in Patients With Huntington's DiseaseWave Life Sciences USA, Inc. · Huntington DiseaseCompletedWVELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 27, 2023ActualPhase 1/Phase 2NCT04931862Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)Wave Life Sciences USA, Inc. · ALSTerminatedWVELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 10, 2021ActualPhase 1/Phase 2NCT03225846Safety and Tolerability of WVE-120102 in Patients With Huntington's DiseaseWave Life Sciences USA, Inc. · Huntington's DiseaseTerminatedWVELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 11, 2021ActualPhase 1/Phase 2NCT03225833Safety and Tolerability of WVE-120101 in Patients With Huntington's DiseaseWave Life Sciences USA, Inc. · Huntington's DiseaseTerminatedWVELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 29, 2021ActualPhase 1/Phase 2NCT04617860Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's DiseaseWave Life Sciences USA, Inc. · Huntington DiseaseTerminatedWVELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 3, 2021ActualPhase 1/Phase 2NCT04617847Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's DiseaseWave Life Sciences USA, Inc. · Huntington DiseaseTerminatedWVELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 16, 2019ActualPhase 2/Phase 3NCT03907072Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular DystrophyWave Life Sciences USA, Inc. · Duchenne Muscular DystrophyTerminatedWVELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 6, 2019ActualPhase 1NCT03508947Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular DystrophyWave Life Sciences USA, Inc. · Duchenne Muscular DystrophyCompletedWVELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 15, 2019ActualNo phase registeredNCT03680365Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of FamiliesJett Foundation, Inc. · Duchenne Muscular Dystrophy
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 15 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner